TABLE OF CONTENTS

SECTION I……..……1-100

1. INTRODUCTION.....1
1.1. Alzheimer's Disease (AD).....1
1.1.1. Cholinergic hypothesis.....4
1.1.2. Amyloid hypothesis.....4
1.1.3. Tau hypothesis.....5
1.2. AD pathogenesis.....6
1.3. Current treatments and existing clinical research on AD.....7
1.3.1. Interferences targeting amyloid.....8
1.3.2. Advanced Glycation End (AGEs) products.....9
1.3.3. NMDA receptor antagonist.....10
1.3.4. Nerve Growth Factor (NGF).....10
1.3.5. Targeting Tau protein.....10
1.3.6. Serotonin receptors.....10
2. RESEARCH ENVISAGED.....12
3. MATERIALS AND METHODS.....14
3.1. Reagents.....14
3.2. Cholinesterase inhibition assay.....14
3.2.1 Principle.....14
3.2.3 Procedure.....15
3.3. *h*AChE induced Aβ aggregation inhibition studies.....16
3.3.1. Reagents.....16
3.3.2. Procedure.....16
3.4. Acute oral toxicity studies.....16
3.5. Scopolamine induced amnesic mice model.....16
3.5.1. Experimental design.....17
3.6. Morris water maze test.....17
3.7. Assessment of lipid peroxidation and endogenous antioxidants.....18
3.7.1. Assay of lipid peroxidation (MDA content).....18
3.7.2. Assay of catalase.....19
3.7.3. AChE and BuChE estimation in brain.....20
3.8. Culture of hippocampal neurons.....21
3.8.1. Determination of cell viability.....21
3.9. Measurement of apoptotic cell death.....21
3.9.1. Reagents.....21
3.9.2. Procedure.....22
3.10. Intracellular ROS generation.....22
3.11. Immunocytochemistry of hippocampal cells treated with $A\beta_{1-42}$.....22
3.11.1. Principle.....22
3.11.2. Reagents.....22
3.11.3. Procedure.....23
3.12. $A\beta_{1-42}$ induced Alzheimer's rat model.....23

3.12.1. Set 1 24
3.12.2. Set 2 24
3.13. Conditioned avoidance response (CAR) 24
3.14. Immunohistochemical analysis of hippocampal neurons 25
3.14.1. Principle 25
3.14.2. Reagents 25
3.14.3. Procedure 26
3.15. Qualitative analysis of Aβ plaques & quantification of β-catenin positive cells 27
3.16. Fluoro-jade C labeling and quantification of fluoro-jade C^+ degenerating neurons 28
3.16.1. Reagents 28
3.16.2. Procedure 28
3.17. Western blot analysis 29
3.17.1. Bicinchoninic acid (BCA) assay 29
3.17.2. Western blot analysis 30
3.18. Statistical analysis 30
4. RESULTS 31
4.1. Cholinesterase inhibition assay of triazine derivatives 31
4.2. Cholinesterase inhibition assay of guanidine derivatives 31
4.3. Morris water maze test 46
4.4. Inhibition of AChE and BuChE activities and antioxidative effects of TRZ-15, TRZ-20 and 3b in scopolamine treated mouse brain 47
4.5. Inhibition of hAChE-induced Aβ aggregation 51
4.6. TRZ-15 and TRZ-20 ameliorate $A\beta_{1-42}$ induced injury in rat hippocampal neurons 51
4.7. Compound (3b) improves $A\beta_{1-42}$ induced injury in rat hippocampal neuronal cells 53
4.8. TRZ-15 and TRZ-20 prevent $A\beta_{1-42}$ induced apoptosis 55
4.9. Compound (3b) prevents apoptosis induced by $A\beta_{1-42}$ 55
4.10. TRZ-15 and TRZ-20 suppress $A\beta_{1-42}$ induced oxidative injury 58
4.11. Compound (3b) represses oxidative injury induced by $A\beta_{1-42}$ 59
4.12. TRZ-15 and TRZ-20 reduced Aβ burden and cleaved caspase-3 expression in rat hippocampal neurons exposed to $A\beta_{1-42}$ 60
4.13. Compound (3b) reduced Aβ burden and cleaved caspase-3 positive expression in rat hippocampal neurons exposed with $A\beta_{1-42}$ 63
4.14. TRZ-15 and TRZ-20 increase hippocampus-dependent learning and memory processes 66
4.15. Compound (3b) augments hippocampus-dependent learning and memory 66
4.16. TRZ-15 and TRZ-20 diminish Aβ burden in $A\beta_{1-42}$ induced Alzheimer's rat brain 67
4.17. Compound (3b) reduces Aβ burden in $A\beta_{1-42}$ induced Alzheimer's rat brain 70
4.18. TRZ-15 and TRZ-20 decrease neurodegeneration in hippocampal region of $A\beta_{1-42}$ induced Alzheimer's rat brain 72
4.19. Compound (3b) diminishes neurodegeneration in hippocampus of $A\beta_{1-42}$ induced Alzheimer's rat brain 72
4.20. TRZ-15 and TRZ-20 stabilize the level of β-catenin in $A\beta_{1-42}$ induced Alzheimer's rat brain 75

4.21. Compound (3b) inhibits GSK-3 and stabilizes the level of β-catenin in $A\beta_{1-42}$ induced Alzheimer's rat brain 77
4.22. TRZ-15 and TRZ-20 reduce Aβ, cytochrome c and cleaved caspase levels in $A\beta_{1-42}$ induced Alzheimer's rat brain 79
4.23. Compound (3b) reduced Aβ, cytochrome c and cleaved caspase-3 levels in $A\beta_{1-42}$ induced Alzheimer's rat brain 81
4.24. TRZ-15 and TRZ-20 diminish GSK3 and increase the level of β-catenin in $A\beta_{1-42}$ induced Alzheimer's rat brain 83
4.25. Compound (3b) inhibits GSK-3 and stabilizes the level of β-catenin in $A\beta_{1-42}$ induced Alzheimer's rat brain 85
5. DISCUSSION 87
5.1. TRZ-15 and TRZ-20 are potent ChE inhibitors and antioxidants 88
5.2. TRZ-15 and TRZ-20 showed protective role in $A\beta_{1-42}$ induced neurotoxicity 89
5.3. TRZ-15 and TRZ-20 are involved in regulation of the wnt signaling pathway 90
5.4. Compound (3b) is a potential anticholinesterase and antioxidant 92
5.5. Compound (3b) shows neuroprotection in $A\beta_{1-42}$ induced neurotoxicity 92
5.6. Compound (3b) inhibits GSK-3 and regulates the canonical Wnt signaling pathway 93
REFERENCES 95
SECTION II 101-151

1. INTRODUCTION 101
1.1. The Discovery of serotonin 101
1.2. Serotonin receptors 102
1.2.1. 5-HT_1 receptors 102
1.2.2. 5-HT_2 receptors 104
1.2.3. 5-HT_3 receptors 106
1.2.4. 5-HT_4 receptors 106
1.2.5. 5-HT_5 receptors 107
1.2.6. 5-HT_6 receptors 107
1.2.7. 5-HT_7 receptors 108
1.3. $5HT_{2C}$ receptor and its therapeutic potentials 108
1.3.1. Obesity 109
1.3.2. Anxiety 110
1.3.3. Depression 111
1.3.4. Penile erection 112
2. RESEARCH ENVISAGED 114
3. MATERIALS AND METHODS 115
3.1. Animals 115
3.2. Methods isolated 115
3.2.1. *In vitro* 5-HT assay using isolated rat fundus preparation 115
3.2.2. *In vitro* 5-HT assay using rat thoracic aorta strip 115
3.2.3. Tail suspension test (TST) in mice 116
3.2.4. Acute oral toxicity study 116
3.2.5. Elevated plus maze (EPM) test 116

3.2.6. Hypophagic response in rats 118
3.2.7. Penile erection rat model....118
3.2.8. Estimation of dopamine (DA) and 5-HT levels using HPLC technique....118
3.3. Statistical analysis....119
4. RESULTS....120
4.1. Biological evaluation....120
4.1.1. *In vitro* isolated rat fundus and isolated rat thoracic aorta experiments....120
4.2. Tail suspension test (TST)....135
4.3. Elevated plus maze test....137
4.4. Hypophagic response....138
4.5. Penile erections in rats....138
4.6. Estimation of monoamines....139
5. DICUSSION....141
REFERENCES....144
SECTION III……152-191

1. INTRODUCTION....152
1.1 Dopaminergic system: synthesis and degeneration of dopamine....152
1.2 Dopaminergic neuronal pathways....153
1.3 Subtypes of dopamine receptors....153
1.4 Importance of D_2 receptor....155
1.5 Parkinson's disease (PD)....155
1.5.1 Pathology, aetiology and pathogenesis....156
1.5.2. Genetics in PD....157
1.5.3. Diagnosis....159
1.5.4. Management....159
2. RESEARCH ENVISAGED....162
3. MATERIALS AND METHODS....163
3.1. Animals....163
3.2. Methodology....163
3.2.1. Superier mesenteric artery strip preparation....163
3.2.4. 6-Hydroxydopamine (6-OHDA) lesioned rat model of Parkinson’s disease....165
3.2.5. Compound (3d) induced rotational behaviour....165
3.2.6. Neurochemical parameters....166
3.2.7. Immunohistochemistry....167
3.2.8. Estimation of dopamine (DA) level using HPLC technique....168
3.3. Statistical Analysis....168
4. RESULTS....169
4.1. Effect of compounds (3a-5) on rat superior mesenteric artery....169
4.2 Compound (3d) improved 6-OHDA induced injury in human SH-SY5Y neuroblastoma cell culture....175
4.4. Antioxidative effects of compound (3d) in 6-OHDA treated rat brain....177
4.5. Compound (3d) increased dopamine (DA) level in striatum of 6-OHDA lesioned rats 179

4.6. Compound (3d) diminishes cleaved caspase-3 level in 6-OHDA induced Parkinson's rat brain.....180
5. DISCUSSION.....182
REFERENCES.....186
SUMMARY.....I
APPENDIX I.....VII
APPENDIX II.....XIV
APPENDIX III.....XXII
APPENDIX IV.....XXX